Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck.
One hundred patients with advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck were treated with chemotherapy and BCG as adjuvant immunotherapy. The overall response rate was 35 per cent, and the median duration of response was seventeen weeks. BCG does not prolong duration of remission or survival time.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D004359:Drug Therapy, Combination; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D011446:Prospective Studies
D000970:Antineoplastic Agents; D001500:BCG Vaccine